Epizyme Inc. (NASDAQ:EPZM)’s share price traded down 11.3% during trading on Monday . The stock traded as low as $9.01 and last traded at $9.15, with a volume of 586,105 shares trading hands. The stock had previously closed at $10.32.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Epizyme from a “buy” rating to a “sell” rating in a research report on Tuesday, July 12th. JMP Securities restated a “buy” rating and set a $28.00 price objective on shares of Epizyme in a research report on Thursday, June 23rd. HC Wainwright restated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Cowen and Company restated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Finally, Leerink Swann restated an “outperform” rating and set a $39.00 price objective on shares of Epizyme in a research report on Tuesday, June 21st. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $23.11.

The firm’s market capitalization is $517.86 million. The firm has a 50 day moving average price of $10.19 and a 200 day moving average price of $10.49.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. Analysts anticipate that Epizyme Inc. will post ($2.25) EPS for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $10.37, for a total value of $41,480.00. Following the completion of the transaction, the insider now directly owns 35,538 shares in the company, valued at approximately $368,529.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

A hedge fund recently bought a new stake in Epizyme stock. California Public Employees Retirement System acquired a new position in Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned approximately 0.41% of Epizyme at the end of the most recent quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.